AUG 07, 2018 11:00 PM PDT

Can a Myeloid Marker Be Helpful in B-cell Neoplasm Diagnostic Testing?

WRITTEN BY: Mauri Brueggeman

Diagnostic testing for hematologic and other cancers has been a traditional method of evaluating, diagnosing, and providing prognostic information to providers choosing treatment and options for oncology patients.  Molecular diagnostics, in particular, have jumped to the forefront of diagnostic testing to provide not only a diagnosis, but to also evaluate the biomarkers present in particular groups of cells; biomarker identification predicts disease behavior, helps in selection of therapeutic treatment targets and options, assists in stratification of disease, and provides a personalized medicine approach. 

Immunophenotyping has become an invaluable diagnostic tool used by clinicians and hematopathologists to fit cancers into appropriate subgroups based on the biomarkers present on tumor involved cell lines. 

There are a multitude of B-cell neoplasms including multiple myeloma, chronic lymphocytic leukemia, small lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, Burkitt’s lymphoma, Mantle cell lymphoma, and others.  In these cases, because they are lymphoid in origin, it is unexpected to find myeloid markers, however, researchers at Stanford and Oregon Health Sciences in Portland found that CD13, a myeloid marker, is expressed in a subset of lymphomas which can be helpful in differentiating between B-cell neoplasms in the clinical setting.

The group published their findings in the International Journal of Laboratory Hematology, which outlined their analysis of 286 mature B-cell neoplasms after immunophenotyping was completed.  CD13 expression was found in cases of lymphoplasmacytic lymphoma (LPL) (61.5% of cases) and FMC7-positive chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (37% of cases).  Notably, there were no cases of follicular lymphoma that expressed CD13. 

The group concluded that CD13 expression is usually present in LPL and FMC7-positive CLL or SLL and is not found in FL.  Historically, CD13 has not been used to characterize B-cell neoplasm subtypes but could be a useful diagnostic means to aid in neoplasm subtyping and furthering B-cell neoplasm therapeutic targeting.

Sources: International Journal of Laboratory Hematology, Archives of Pathology & Laboratory Medicine, Clinics in Oncology , Modern Pathology 

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
NOV 24, 2019
Genetics & Genomics
NOV 24, 2019
22 Genes Discovered that Predict Skin Cancer from Sun Exposure
Australia has the highest rate of skin cancer in the world, with around 49 cases per 100,000 people. Now, researchers at the QIMR Berghofer Medical Researc...
DEC 25, 2019
Drug Discovery & Development
DEC 25, 2019
New Drug to Make Breast Cancer Treatment More Affordable
The US Food and Drug Administration has granted accelerated approval to new breast cancer drug, trastuzumab deruxtecan. The drug’s increasing recogni...
DEC 23, 2019
Technology
DEC 23, 2019
Can Artifical Intelligence Detect Leukemia?
Artificial intelligence has always been a hot topic of discussion in the medical sciences with a whirlwind of applications. However, know the latest curios...
FEB 04, 2020
Cancer
FEB 04, 2020
The role of SRR in colorectal cancer
Researchers from Osaka University have recently discovered a new function of the multifunctional enzyme entitled serine racemase (SRR). According to the te...
FEB 14, 2020
Cancer
FEB 14, 2020
Cataloging Cancer: DNA fingerprints at work
New research published as part of a global Pan-Cancer Project highlights the world’s most comprehensive catalog to date of DNA fingerprints of cancer...
FEB 11, 2020
Cancer
FEB 11, 2020
Could we be over-diagnosing cancer?
Roughly one in every two people are estimated to receive a cancer diagnosis at some point in their lives, but are all of those diagnoses valid? New researc...
Loading Comments...